As stated in the previous section, the data presented in Table 1 and Table 2 yielded the null presence of CYP2D6 genotyping tests for tamoxifen, in public sector, and therefore, the complete absence of systematic public genetic control of BC patients regarding their response to tamoxifen. Here, CYP2D6 is linked to breast cancer.